SGIOF:OTC-Shionogi & Co. Ltd (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 54.10

Change

-0.65 (-1.19)%

Market Cap

USD 16.54B

Volume

8.68K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Shionogi & Co. Ltd (SGIOF) Stock Analysis:
Based on the Shionogi & Co. Ltd stock forecasts from 0 analysts, the average analyst target price for Shionogi & Co. Ltd is not available over the next 12 months. Shionogi & Co. Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Shionogi & Co. Ltd is Slightly Bullish , which is based on 8 positive signals and 4 negative signals. At the last closing, Shionogi & Co. Ltd’s stock price was USD 54.10. Shionogi & Co. Ltd’s stock price has changed by -0.18% over the past week, +1.12% over the past month and +0.65% over the last year.

No recent analyst target price found for Shionogi & Co. Ltd
No recent average analyst rating found for Shionogi & Co. Ltd

About

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus dr ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.25 (+0.67%)

USD79.69B 26.13 14.59
MKGAF MERCK Kommanditgesellschaft au..

+1.00 (+0.53%)

USD79.29B 23.81 14.59
TKPHF Takeda Pharmaceutical Company ..

N/A

USD45.29B 25.39 0.07
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD15.66B 16.92 2.59
GNHAF Vifor Pharma AG

N/A

USD12.87B 76.02 17.58
ESALF Eisai Co. Ltd

N/A

USD12.28B 32.74 0.10
ESALY Eisai Co. Ltd

-0.79 (-1.81%)

USD12.24B 32.51 0.10
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
IPSEF Ipsen S.A

N/A

USD9.62B 14.22 7.57
TEVJF Teva Pharmaceutical Industries..

N/A

USD9.36B 22.30 18.11

ETFs Containing SGIOF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.07% 57% F 38% F
Dividend Return 77.19% 71% C- 91% A-
Total Return 53.12% 90% A- 91% A-
Trailing 12 Months  
Capital Gain 3.84% 91% A- 77% C+
Dividend Return 106.54% 84% B 92% A-
Total Return 110.38% 97% A+ 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.53% 43% F 40% F
Dividend Return 3.94% 75% C 68% D+
Total Return 8.47% 46% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 24.05% 94% A 76% C
Risk Adjusted Return 35.22% 73% C 60% D-
Market Capitalization 16.54B 99% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.50 35% F 35% F
Price/Book Ratio 2.31 37% F 38% F
Price / Cash Flow Ratio 0.16 26% F 46% F
EV/EBITDA 0.11 85% B 80% B-
Management Effectiveness  
Return on Equity 12.21% 86% B 70% C-
Return on Invested Capital -3.03% 54% F 36% F
Return on Assets 6.42% 91% A- 85% B
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 1.74% 40% F 20% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.82 55% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.